Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.79 |
| ▸ | MET | P08581 | 2/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.67 |
| ▸ | KDR | P35968 | 9/20 | 0.67 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050336 | 1.00 | DDR2 (0.79) | DDR2METPDGFRAKDRFGFR2 | |
| SCHEMBL30050049 | 0.89 | DDR2 (0.70) | DDR2METPDGFRAKDRFGFR2 | |
| SCHEMBL29317873 | 0.89 | DDR2 (0.70) | DDR2METPDGFRAKDRFGFR2 | |
| SCHEMBL29317907 | 0.88 | DDR2 (0.69) | DDR2METPDGFRAKDRAXL | |
| SCHEMBL30049330 | 0.88 | DDR2 (0.69) | DDR2METPDGFRAKDRAXL | |
| SCHEMBL29317847 | 0.88 | DDR2 (1.00) | DDR2METPDGFRAKDRFGFR2 | |
| SCHEMBL30050488 | 0.88 | DDR2 (1.00) | DDR2METPDGFRAKDRFGFR2 | |
| SCHEMBL7482526 | 0.86 | PDGFRA (0.89) | PDGFRAKDR | |
| SCHEMBL29317854 | 0.86 | DDR2 (0.83) | DDR2METPDGFRAKDRFGFR2 | |
| SCHEMBL29317838 | 0.86 | DDR2 (0.79) | DDR2METPDGFRAKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | DDR2 4341/4885MET 4678/4885PDGFRA 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.